Cell cryopreservation is a process of freezing cells at utmost low temperatures, usually below -130°C. The process ensures maintenance of biological samples under suspended simulation at cryogenic temperatures allowing to reserve the fine structure of cells for a prolonged period. The cells under scope are typically mixed with a cryoprotectant agent or CPA. The mixing of cells with cryoprotectant ensures the rate of water transport, nucleation, and ice growth while simultaneously rendering protective properties to ensure the cryopreserved cells. The growing base for clinical research and development of stem cell therapies have fueled the market growth. Additionally, the growing support from government agencies, surge in prevalence of chronic ailments across geographies, and the ability to provide resources for future drug research developments boosts the cell cryopreservation market.
Recently, adult stem cells research has been gaining immense traction as these cells are capable to differentiate between various forms of specific cells and can be obtained from various locations such as bone marrow, fat tissue, umbilical cord blood, and others. Stem cells application is largely dependent on cell cryopreservation, as it allows to preserve, store, and transport stem cells without any form of cellular or genetic modification. Furthermore, stem cells have the potential to replace damaged or diseased cells in the body, and regenerative medicine seeks to harness this potential to develop new therapies for a range of conditions, including cardiovascular disease, diabetes, and neurological disorders. For instance, as per CDC 2022, around 523 million people globally are living with some form of cardiovascular condition in 2020. A rampant growth in the geriatric population along with sedentary form of lifestyle will increase the burden of cardiovascular disease, supporting the growth of regenerative medicine and cell cryopreservation market.
Development of new cryoprotectants has allowed for efficiently managing the cell survival during the freezing and thawing stage, additionally, new elements in the cryoprotectants can enhance the cell viability and reduce overall damage. For instance, in April 2023, an article from South China University of Technology in Guangzhou China, mentioned the discovery of nanolayers made from metal-organic frameworks on the metal hafnium. The nanolayer shall prevent any form of ice-crystal formations at extremely low concentrations and efficiently protect red blood cells during the thawing and freezing in cryopreservation. The following advancements will allow for effective cryopreservation of cells for bioscientific research and development.
Moreover, newer technologies are being introduced in the sphere of cryopreservation which has positively impacted the market growth. For instance, in December 2021, Evia Bio launched a newer form of cryopreservation technology to be used for cell and gene therapies. The solution is osmolyte based, which enhances the cell survival rate, and is termed better than the commercially available dimethyl sulfoxide (DSMO). The solution can be primarily applied for induced pluripotent stem cells (IPSCs), as they are specifically sensitive to freezing. In addition, single-use containers and assemblies in biopharmaceutical industry are gaining immense traction, especially in critical steps such as freezing & thawing, filling and draining, storage and shipping of various forms of drug substances. For instance, in October 2022, Single Use Support GmbH launched single-use bioprocess containers under the brand name of IRIS which can be universally applicable for bioprocessing and cryopreservation of various forms of biologics, cell and gene therapies, and others. By introducing single-use technologies in cryopreservation market, industrial players gain scalability and commercialization advantages.
The cell cryopreservation market is segmented based on type, application, end-user, and region. The type segment includes cryopreservation media agents and equipment. The application segment is segmented into stem cells, oocytes and embryotic cells, sperm cells, hepatocytes, and others. The end-user segment is further segmented into biobanks, biopharmaceutical & pharmaceutical companies, academic & research institutes, and others.
Segments |
Details |
Product Type |
|
Application |
|
End user |
|
Region |
|
Various major companies are operating in the cell cryopreservation market. Some of the prominent players in the market include: Thermo Fisher Inc, Merck KGaA, Sartorius AG, PromoCell GmbH, Lonza, HiMedia Laboratories, Eppendorf Corporate, Danaher, Creative Biolabs, and Corning Incorporated.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.